06-Feb-18, ET Healthworld
As the first anniversary of the price capping of cardiac stents in India draws near, medical device manufacturers and related associations assembled at the National Pharmaceutical Pricing Authority (NAPPA) to argue against the current price caps.
%20ET%20Healthworld.jpg "Indias price cap on cardiac stents stifling innovation (c) ET Healthworld")
Image: ET Healthworld
According to industry leaders, the price cap has left little room for innovation, leaving patients with few options.
The industry leaders demanded the expansion of the National List of Essential Medicines (NLEM) board evaluating the price-capping issue by including different stakeholders with fair representation.